Appeals court reignites CRISPR discovery row, raising questions about gene editing biotech patents
An appeals court has opened another chapter in the long-running CRISPR patent saga. Three years after a patent body ruled in favor of the teams behind Editas Medicine’s intellectual property, an appeals court has found fault with the decision and sent the case back for reassessment.
An appeals court has opened another chapter in the long-running CRISPR patent saga. Three years after a patent body ruled in favor of the teams behind Editas Medicine’s intellectual property, an appeals court has found fault with the decision and sent the case back for reassessment.
